Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Correction to *Lancet Respir Med* 2021; published online Sept 1. https://doi.org/10.1016/S2213-2600(21)00331-3

Published Online
September 8, 2021
https://doi.org/10.1016/S2213-2600(21)00410-0

Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med *2021; published online Sept 1. https://doi.org/10.1016/S2213-2600(21)00331-3*—In this Article, in figure 2A the number at risk for the baricitinib group at Day 14 should be 684. This correction has been made to the online version as of Sept 8, 2021 and will be made to the printed version.

Correction to *Lancet Respir Med* 2021; 9: 1130–40

Published Online
September 2, 2021
http://dx.doi.org/10.1016/S2213-2600(21)00374-X

Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med *2021;* **9:** *1130–40*—The appendix of this Article has been corrected and the data in the following Results text is now corrected: "...while systemic corticosteroids were co-prescribed in 13 (9%) receiving azithromycin". These corrections have been made to the online version as of Sept 2, 2021, and will be made to the printed version.